Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 22Dexamethasone 15Cytarabine 15venetoclax 14Vincristine 13Methotrexate 10Etoposide 10Prednisone 9Doxorubicin 9Calcium Dobesilate 9prednylidene 8dexamethasone acetate 8dexamethasone 21-phosphate 8deltacortene 8auricularum 8merphos 7Specimen Handling 7pegaspargase 6fludarabine phosphate 6daratumumab 6calaspargase pegol 6Mercaptopurine 6Granulocyte Colony-Stimulating Factor 6fludarabine 5Stem Cell Transplantation 5Filgrastim 5Daunorubicin 5Bortezomib 5Biopsy 5Azacitidine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × EPOCH protocol × 1 year × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡